7.72
-0.465(-5.68%)
Currency In USD
| Previous Close | 8.18 |
| Open | 8 |
| Day High | 8.09 |
| Day Low | 6.6 |
| 52-Week High | 8.72 |
| 52-Week Low | 2.41 |
| Volume | 4.24M |
| Average Volume | 1.21M |
| Market Cap | 601.08M |
| PE | -3.11 |
| EPS | -2.48 |
| Moving Average 50 Days | 6.12 |
| Moving Average 200 Days | 5.57 |
| Change | -0.47 |
If you invested $1000 in Solid Biosciences Inc. (SLDB) since IPO date, it would be worth $23.08 as of March 11, 2026 at a share price of $7.83. Whereas If you bought $1000 worth of Solid Biosciences Inc. (SLDB) shares 5 years ago, it would be worth $55.77 as of March 11, 2026 at a share price of $7.83.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial
GlobeNewswire Inc.
4 hours ago
- 40 participants have been dosed with SGT-003 in the INSPIRE DUCHENNE trial to date - - Robust microdystrophin expression with consistent mechanistic evidence of dystrophin associated protein complex (DAPC) restoration and improvements in muscle int
Solid Biosciences Announces Oversubscribed $240 Million Private Placement
GlobeNewswire Inc.
Mar 06, 2026 1:31 PM GMT
CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has entered into a securiti
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
GlobeNewswire Inc.
Mar 06, 2026 1:30 PM GMT
CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced presentations on SGT-003, its next-